Great Elm Capital Corp. Prices Public Offering of $36,000,000 of 8.125% Notes Due 2029

Stock Information for Lineage Cell Therapeutics, Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Lineage Cell Therapeutics, Inc.

Great Elm Capital Corp. Announces Fourth Quarter and Full Year 2024 Financial Results
Great Elm Capital Corp. ("GECC") Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call
Great Elm Capital Corp. ("GECC") Declares $0.05 Per Common Share Special Cash Distribution and Approves First Quarter 2025 Distribution of $0.37 Per Common Share
Great Elm Capital Corp. ("GECC") Raises $13.2 Million of Equity at Net Asset Value
Great Elm Capital Corp. Announces Third Quarter 2024 Financial Results
Great Elm Capital Corp. ("GECC") Schedules Third Quarter 2024 Earnings Release and Conference Call
Great Elm Capital Corp. Announces Conditional Redemption of 6.75% Notes due 2025
Great Elm Capital Corp. Announces Public Offering of Unsecured Notes

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.